Publications

TitleTreatment of Vancomycin-Resistant Enterococcus Faecium Infections with Quinupristin/Dalfopristin
AuthorsLinden P. K., Moellering R. C. Jr., Wood C. A., Rehm S. J., Flaherty J., Bompart F., Talbot G. H., Hamer, D.H. (Synercid Emergency-Use Study Group)
PublicationClin Infect Dis. 2001 Oct; 33(11):1816-23.
AbstractClinicians caring for patients with vancomycin-resistant Enterococcus faecium (VREF) infections face severe constraints in the selection of treatment. Quinupristin/dalfopristin (Synercid) is active in vitro against VREF, with a MIC(90) of 1.0 microg/mL. We investigated the clinical efficacy and safety of this agent in a multicenter, prospective, noncomparative, emergency-use study of 396 patients. Patients were included if they had signs and symptoms of active infection, including bacteremia of unknown origin, intra-abdominal infection, and skin and skin-structure infection, with no alternative antibiotic therapy available. The mean duration of treatment was 20 days (range, 4-40 days). The clinical response rate was 68.8% in the evaluable subset, and the overall response rate was 65.6%. The most common adverse events related to quinupristin/dalfopristin were arthralgias and myalgias. Related laboratory abnormalities were rare. In this severely ill patient population, quinupristin/dalfopristin was efficacious and demonstrated an acceptable safety profile in the treatment of VREF infection.
URLhttp://www.ncbi.nlm.nih.gov/pubmed/11668430
Full TextDownload Document